Ichthammol 1% / Clioquinol 3% in Hydrocortisone 1% ointment
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 48 studies.
1942–2025
Showing all 48 studies, sorted by most relevant.
Oxford English Dictionary, 2023
Sanjay Kumar *, Kashiroygoud Biradar, Sudheer Kumar M, et al.
Journal of Clinical Otorhinolaryngology, 2023
Background:Otitis externa worsened by furunculosis is a common ear disorder marked by ear canal inflammation and infection, frequently accompanied by uncomfortable furuncles. Topical antibiotics and steroids are frequently used in conjunction with each other to treat this illness effectively. This study compared the effectiveness and safety of three different treatment regimens for treating otitis externa complicated by furunculosis: gentamicin with hydrocortisone (Treatment Group A), glycerol/ichthammol solution (Treatment Group B), and aluminium acetate solution (Treatment Group C). Methods: A prospective cohort study involving 300 individuals with otitis externa and furunculosis was carried out. The patients were allocated evenly among the three therapy groups: Group A received gentamicin mixed with hydrocortisone; Group B received glycerol/ichthammol solution; and Group C received aluminium acetate solution. Reduction in pain intensity and remission of inflammation were the main results. Changes in life quality and safety outcomes in terms of adverse occurrences were considered secondary outcomes. Age-based subgroup analysis was carried out, and linear regression analysis was used to assess the correlations between factors and results. Results: When compared to Group B and Group C, Group A had a marginally better therapeutic result in terms of reducing pain and inflammation. Although adverse events including skin irritability and allergic responses were more frequent in Group A, they were also more frequent overall. In all three treatment groups, younger patients generally had higher resolution rates, according to subgroup analysis based on age. Age and gender did not demonstrate a significant relationship, but linear regression analysis revealed a significant association between the type of treatment and therapeutic outcomes. Conclusion:In comparison to glycerol/ichthammol solution and aluminium acetate solution, the combination of gentamicin and hydrocortisone showed marginally greater efficiency in treating otitis externa complicated by furunculosis. The combination of gentamicin and hydrocortisone, however, was linked to a somewhat increased frequency of adverse effects. When choosing the best course of treatment, doctors should take into account the trade-offs between efficacy and safety while also taking into account the unique characteristics of each patient. To confirm and build upon these findings, additional research with bigger sample sizes and various demographics is necessary.
Abstract licence: CC BY
Shyamala K, Mohana Karthikeyan S, Sheetal K
Cureus, 2024
Oxford English Dictionary, 2023
Jeferson Luis Franco
Advances in Clinical Toxicology, 2023
Saai Ram Thejas, Sindu Mohan, Bathula Deepthi
Indian Journal of Otology, 2025
Abstract Background: Acute Otitis Externa (AOE) is diffuse inflammation of the external auditory canal. Findings show a narrowed, tender and erythematous external auditory canal. There are no concrete methods in the management of AOE. Current methods include aural toileting and application of topical agents. Betamethasone Valerate, a Corticosteroid and 0.1% w/w of drug is used most commonly. The commercially used 10% Ichthammol Glycerin solution is a mixture of pure Glycerol [C3H8O3] in a 9:1 ratio with Ichthammol. Methods: All patients presenting to the Department of Otorhinolaryngology of a Rural Hospital in South India diagnosed with AOE between were included in study. Thirty were assigned to each group. Group A had IG and Group B had BV placed in their ear canal with the help of a sterile cotton wick at 0, 24 and 48 hour. The Visual Analogue Scale and Edema Erythema Index were used as parameters of assessment. Results: The EET improvement stood at 51.31% in Group A. The EET improvement stood at 47.96% in Group B. In Group A, VAS had an improvement of 63.85%. In Group B, VAS had an improvement of 49.42%. Conclusion: The use of IG was found to be superior to BV in the management of AOE. IG provides relief from topical allergy and irritation along with reduction of edema. Since IG is cheaper and easy to procure, it can be used as a first line treatment in the management of AOE.
Abstract licence: CC BY-NC-SA 4.0
Mona Kamel Ahmed, Adel Magdy Michael, Said Abdel-Monem Hassan, et al.
European Journal of Chemistry, 2021
Minnu Thomas
Journal of Medical Science And clinical Research, 2016
CABI Compendium, 2017
Chemical Effects in Biological Systems (CEBS), 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.